115 related articles for article (PubMed ID: 22175076)
1. In vogue with venture.
Patou G
Nat Biotechnol; 2011 Nov; 29(11):967-9. PubMed ID: 22175076
[No Abstract] [Full Text] [Related]
2. Biopharmaceutical process development - shortcut to market: an interview with Rolf Werner from Boehringer Ingelheim.
Jungbauer A; Göbel U
Biotechnol J; 2012 Jan; 7(1):14-6. PubMed ID: 22228694
[No Abstract] [Full Text] [Related]
3. Industry sponsored bias in cost effectiveness analyses.
John-Baptiste A; Bell C
BMJ; 2010 Oct; 341():c5350. PubMed ID: 20943724
[No Abstract] [Full Text] [Related]
4. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
5. Members need only apply.
Nat Biotechnol; 2011 Jul; 29(7):551. PubMed ID: 21747362
[No Abstract] [Full Text] [Related]
6. Open-minded to open innovation and precompetitive collaboration.
Wagner JA
Clin Pharmacol Ther; 2010 May; 87(5):511-5. PubMed ID: 20407451
[No Abstract] [Full Text] [Related]
7. The Medicines Company: an emerging pharmaceutical company in cardiology is spearheading an innovative approach to critical care medicines.
Mayor S
Eur Heart J; 2009 Jul; 30(13):1541-3. PubMed ID: 19579293
[No Abstract] [Full Text] [Related]
8. For-profit clinical trials in developing countries--those troublesome patient benefits.
Schuklenk U
Am J Bioeth; 2010 Jun; 10(6):52-4. PubMed ID: 20526975
[No Abstract] [Full Text] [Related]
9. A cancer drug shows promise, at a price that many can't pay.
Berenson A
N Y Times Web; 2006 Feb; ():A1, C2. PubMed ID: 16506302
[No Abstract] [Full Text] [Related]
10. Market watch: industry perspectives on personalized medicine.
Zuckerman R; Milne CP
Nat Rev Drug Discov; 2012 Mar; 11(3):178. PubMed ID: 22378258
[No Abstract] [Full Text] [Related]
11. Nutraceuticals: poised for a healthy slice of the healthcare market?
Brower V
Nat Biotechnol; 1998 Aug; 16(8):728-31. PubMed ID: 9702769
[No Abstract] [Full Text] [Related]
12. Spat over IMI funding and intellectual property.
Sinha G
Nat Biotechnol; 2011 Jun; 29(6):473. PubMed ID: 21654659
[No Abstract] [Full Text] [Related]
13. Few US medical schools and medical centres are disclosing industry ties.
Tanne JH
BMJ; 2010 Feb; 340():c1075. PubMed ID: 20179129
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: business practices. Issue brief.
Thomson Reuters/West
Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840
[No Abstract] [Full Text] [Related]
15. Vulnerability of health to market forces.
Brezis M; Wiist WH
Med Care; 2011 Mar; 49(3):232-9. PubMed ID: 21301368
[TBL] [Abstract][Full Text] [Related]
16. Justice in the application of science: beyond fair benefits.
London AJ
Am J Bioeth; 2010 Jun; 10(6):54-6. PubMed ID: 20526976
[No Abstract] [Full Text] [Related]
17. Response to open peer commentaries on "How to do research fairly in an unjust world".
Ballantyne AJ
Am J Bioeth; 2010 Jun; 10(6):W4-6. PubMed ID: 20526959
[No Abstract] [Full Text] [Related]
18. An audience with Luciano Rossetti. Interview by Bethan Hughes.
Rossetti L
Nat Rev Drug Discov; 2010 Oct; 9(10):758. PubMed ID: 20885401
[No Abstract] [Full Text] [Related]
19. Healthcare in Syria is close to collapse as drug shortages bite.
Pitts-Tucker T
BMJ; 2012 Aug; 345():e5410. PubMed ID: 22879641
[No Abstract] [Full Text] [Related]
20. Market watch: upcoming market catalysts in Q4 2010.
Rosenthal J
Nat Rev Drug Discov; 2010 Oct; 9(10):755. PubMed ID: 20885399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
